In This Section

Home / Blurb / Discussion List

FDA Approves Atezolizumab Plus Nab-paclitaxel for TNBC

Mar 8, 2019, 15:07 PM
On March 8, the FDA approved atezolizumab (Tecentriq, Genentech Inc.) plus nab-paclitaxel (Abraxane, Celgene) for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).

Read OncLive news coverage here

Posted 3/8/2019

Leave a comment